a:head bio

Executive Summary

a:head bio AG is an Austrian biotechnology company founded in 2020 and headquartered in Vienna, dedicated to transforming neuroscience drug discovery by replacing outdated preclinical models with human-relevant biology. The company focuses on developing novel therapeutics for psychiatric and neurological disorders with high unmet medical need, where current treatments are inadequate or non-existent. By leveraging advanced human-based platforms, a:head bio aims to improve translational success and accelerate the development of effective therapies for conditions such as depression, anxiety, and neurodegenerative diseases. The company was identified through biopharmguy and is currently at an early stage, with no disclosed funding or valuation details. However, its innovative approach and focus on high-need areas position it as a potentially impactful player in the neuroscience space, pending execution of key milestones and validation from partners or investors.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round50% success
• Q2 2027Lead Program Nomination40% success
• Q1 2027Pharma Partnership or Collaboration30% success